See more : Synopsys, Inc. (SYP.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Beijing Leadman Biochemistry Co.,Ltd. (300289.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Beijing Leadman Biochemistry Co.,Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
- Bellway p.l.c. (BLWYF) Income Statement Analysis – Financial Results
- Britannia Industries Limited (BRITANNIA.BO) Income Statement Analysis – Financial Results
- Union Technologies Informatique Group S.A. (FPG.PA) Income Statement Analysis – Financial Results
- Orpea SA (ORRRY) Income Statement Analysis – Financial Results
- CareNet, Inc. (2150.T) Income Statement Analysis – Financial Results
Beijing Leadman Biochemistry Co.,Ltd. (300289.SZ)
About Beijing Leadman Biochemistry Co.,Ltd.
Beijing Leadman Biochemistry Co.,Ltd. engages in the research and development, manufacture, and sale of in vitro diagnostic products in the People's Republic of China. The company offers biochemical raw materials, such as enzymes, coenzymes, antibodies, buffers, enzyme substrates, culture media, stain reagents, amino acids, and other products primarily for biotechnology, clinical diagnosis, drug development, chemical production, and other related applications. It also provides biochemistry diagnostic and companion reagents. In addition, the company offers medical instruments, such as EnigmaML, an automated molecular test platform for use in clinical laboratory and at the point-of-care, including clinics, doctor's surgeries, and pharmacies; DiaSys InnovaStar, an automatic compact POCT analyzer to deliver result quality comparable to measurements on laboratory analyzers; DiaSys Respons, a random access bench top analyzer; CI1000 automatic chemiluminescence immunoassay analyzers; and IDS-isys, an instrument to enhance performance and productivity. The company was founded in 1997 and is headquartered in Beijing, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 461.55M | 705.98M | 564.06M | 471.51M | 515.14M | 654.80M | 575.98M | 533.39M | 681.68M | 536.97M | 343.63M | 317.27M | 252.08M | 185.62M | 143.27M | 103.81M |
| Cost of Revenue | 198.01M | 405.62M | 268.10M | 215.44M | 233.40M | 332.04M | 258.33M | 239.09M | 287.88M | 204.96M | 126.61M | 119.62M | 96.70M | 65.40M | 57.19M | 41.94M |
| Gross Profit | 263.55M | 300.36M | 295.95M | 256.07M | 281.74M | 322.76M | 317.64M | 294.30M | 393.79M | 332.01M | 217.02M | 197.66M | 155.39M | 120.22M | 86.08M | 61.87M |
| Gross Profit Ratio | 57.10% | 42.55% | 52.47% | 54.31% | 54.69% | 49.29% | 55.15% | 55.18% | 57.77% | 61.83% | 63.16% | 62.30% | 61.64% | 64.77% | 60.08% | 59.60% |
| Research & Development | 36.87M | 34.96M | 32.75M | 38.47M | 48.31M | 39.97M | 36.78M | 31.45M | 29.43M | 28.00M | 24.38M | 23.09M | 16.22M | 11.73M | 6.22M | 5.09M |
| General & Administrative | 63.25M | 19.03M | 18.25M | 16.52M | 16.76M | 22.39M | 23.40M | 21.03M | 33.96M | 18.71M | 6.84M | 5.66M | 5.07M | 4.16M | 4.21M | 2.35M |
| Selling & Marketing | 31.91M | 120.10M | 102.49M | 90.70M | 94.84M | 95.57M | 72.85M | 60.05M | 43.50M | 41.31M | 37.89M | 34.87M | 27.33M | 24.24M | 13.12M | 10.76M |
| SG&A | 194.87M | 139.13M | 120.75M | 107.21M | 111.60M | 117.96M | 96.25M | 81.08M | 77.46M | 60.02M | 44.73M | 40.53M | 32.40M | 28.40M | 17.33M | 13.11M |
| Other Expenses | 7.90M | -30.73M | 2.09M | 1.26M | 116.84K | -178.73K | 1.97M | 12.15M | 10.70M | 6.10M | 3.00M | 3.78M | 336.88K | 886.64K | 1.75M | 532.21K |
| Operating Expenses | 239.64M | 251.74M | 220.47M | 201.86M | 224.33M | 215.79M | 182.93M | 176.30M | 171.46M | 149.81M | 96.36M | 83.87M | 65.88M | 55.84M | 37.00M | 27.10M |
| Cost & Expenses | 437.65M | 657.36M | 488.57M | 417.30M | 457.73M | 547.83M | 441.26M | 415.39M | 459.35M | 354.77M | 222.97M | 203.49M | 162.57M | 121.24M | 94.19M | 69.04M |
| Interest Income | 13.60M | 14.61M | 7.97M | 4.48M | 3.01M | 4.16M | 4.11M | 2.41M | 910.92K | 7.82M | 8.04M | 1.68M | 369.00K | 144.98K | 398.22K | 153.14K |
| Interest Expense | 737.03K | 1.29M | 2.15M | 2.56M | 3.98M | 6.23M | 9.33M | 7.83M | 14.47M | 19.05M | 2.61M | 2.20M | 3.28M | 1.45M | 506.67K | 495.63K |
| Depreciation & Amortization | 61.69M | 60.29M | 57.33M | 56.65M | 53.21M | 42.07M | 39.61M | 32.88M | 51.64M | 45.23M | 16.85M | 8.85M | 7.19M | 4.87M | 3.40M | 2.92M |
| EBITDA | 86.96M | 36.52M | 119.90M | 44.84M | 79.59M | 119.41M | 168.85M | 148.92M | 275.18M | 216.58M | 147.72M | 126.06M | 93.97M | 69.09M | 53.39M | 38.51M |
| EBITDA Ratio | 18.84% | 13.99% | 25.81% | 24.21% | 20.09% | 22.75% | 31.19% | 32.68% | 41.69% | 45.25% | 43.68% | 40.43% | 38.51% | 37.82% | 37.82% | 37.42% |
| Operating Income | 23.91M | 7.56M | 60.19M | -7.79M | 31.40M | 72.79M | 117.15M | 95.63M | 198.51M | 161.74M | 125.27M | 111.05M | 83.15M | 61.90M | 47.80M | 34.56M |
| Operating Income Ratio | 5.18% | 1.07% | 10.67% | -1.65% | 6.10% | 11.12% | 20.34% | 17.93% | 29.12% | 30.12% | 36.45% | 35.00% | 32.99% | 33.35% | 33.36% | 33.29% |
| Total Other Income/Expenses | 626.36K | -32.73M | -1.38M | -7.00M | 116.84K | -178.73K | 1.97M | 12.15M | 10.57M | 6.05M | 2.99M | 3.77M | 336.88K | 878.07K | 1.68M | 532.21K |
| Income Before Tax | 24.53M | -25.16M | 58.80M | -14.79M | 31.52M | 72.61M | 119.12M | 107.78M | 209.07M | 167.80M | 128.26M | 114.82M | 83.49M | 62.78M | 49.48M | 35.09M |
| Income Before Tax Ratio | 5.32% | -3.56% | 10.42% | -3.14% | 6.12% | 11.09% | 20.68% | 20.21% | 30.67% | 31.25% | 37.32% | 36.19% | 33.12% | 33.82% | 34.54% | 33.80% |
| Income Tax Expense | 1.87M | 10.87M | 11.62M | 14.63M | 3.55M | 10.45M | 18.10M | 16.15M | 30.95M | 24.08M | 18.19M | 16.54M | 11.64M | 8.38M | 8.06M | 8.93M |
| Net Income | 15.34M | -56.27M | 22.42M | -50.98M | 6.31M | 40.47M | 73.07M | 69.65M | 157.22M | 128.28M | 110.07M | 98.29M | 71.85M | 54.40M | 41.41M | 26.16M |
| Net Income Ratio | 3.32% | -7.97% | 3.97% | -10.81% | 1.22% | 6.18% | 12.69% | 13.06% | 23.06% | 23.89% | 32.03% | 30.98% | 28.50% | 29.31% | 28.91% | 25.20% |
| EPS | 0.03 | -0.10 | 0.05 | -0.12 | 0.02 | 0.10 | 0.17 | 0.17 | 0.40 | 0.33 | 0.29 | 0.27 | 0.25 | 0.19 | 0.14 | 0.09 |
| EPS Diluted | 0.03 | -0.10 | 0.05 | -0.12 | 0.02 | 0.10 | 0.17 | 0.17 | 0.39 | 0.33 | 0.29 | 0.27 | 0.25 | 0.19 | 0.14 | 0.09 |
| Weighted Avg Shares Out | 511.25M | 544.01M | 448.38M | 417.80M | 417.80M | 419.83M | 423.81M | 409.70M | 393.05M | 388.73M | 382.19M | 366.74M | 289.72M | 289.35M | 287.60M | 284.37M |
| Weighted Avg Shares Out (Dil) | 511.25M | 544.01M | 448.38M | 417.80M | 417.80M | 421.14M | 429.81M | 409.70M | 403.13M | 388.73M | 382.19M | 366.74M | 289.72M | 289.35M | 287.60M | 284.37M |
Source: https://incomestatements.info
Category: Stock Reports